Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

In this study, tofacitinib treatment for six months significantly reduced hair loss severity in alopecia areata patients.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.

In this report, a 58-year-old woman with ocular myasthenia gravis experienced complete resolution of symptoms and hair regrowth after six months of treatment with the JAK inhibitor baricitinib, highlighting a potential new therapeutic approach for this condition.

This study suggests that oral JAK inhibitors can be an effective treatment option for approximately half of patients with moderate to severe alopecia areata, despite variable responses and potential adverse effects.

JAK inhibitors might help treat alopecia areata.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This case report details the first use of baricitinib in a pediatric patient with immune thrombocytopenia and alopecia areata, showing successful treatment with increased platelet counts.

This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This article reviews the use of tofacitinib for rheumatoid and psoriatic arthritis and alopecia areata, noting potential serious side effects, but reports no cases of palmoplantar pustulosis from the therapy.

This research letter discusses the use of Janus kinase inhibitors for treating lichen planopilaris, although specific results or conclusions from the study are not provided.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.

This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.

This study surveyed Irish dermatologists and found that while JAK inhibitors show promising efficacy for alopecia areata, there is significant variation in practice due to the lack of specific guidelines and long-term safety data for these treatments.

This article is a Letter to the Editor discussing rebound effects associated with JAK inhibitor use in treating alopecia areata and reports no new clinical results.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

In this case report, a woman with ulcerative colitis experienced clinical deterioration during upadacitinib therapy, which improved after discontinuation, strongly suggesting drug hypersensitivity to the Janus kinase inhibitor as a potential cause for her symptoms.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.